BRAF and melanoma: The development of inhibitors targeting MEK1/2 kinases, has yielded the non-ATP-competitive allosteric inhibitors trametinib, cobimetinib [129] and binimetinib, which brought hope for non-BRAF-mutant melanoma cases.